Date: Tuesday 13 Aug 2013
LONDON (ShareCast) - ImmuPharma, a drug developer, has reported that its lead cancer programme, IPP-204106, is progressing, and that trials are being conducted at three hospitals across Europe to identify the optimal dose for treating patients.
IPP-204106 is 10 times more efficient that the previous Nucant version in pre-clinical cancer models, the group said.
The trial will be followed by a Phase II efficacy study designed to treat various cancers, in approximately 30 patients, to identify appropriate biomarkers.
Dr Robert Zimmer, MD, PhD, ImmuPharma's President and Chief Scientific Officer commented: "The clinical development of our cancer programme continues to be a key priority for ImmuPharma. We look forward to announcing interim results from the current trial in the near future."
Patients that are being enrolled in the trial are in a serious condition, suffering from a range of cancers, all have metastasis (tumour spreading) and have failed their previous treatment, the company said.
In the future the group plans to conduct more focused follow-up studies on patients with glioblastoma (brain tumour), metastatic melanoma, and pancreatic cancer where nucleolin plays a key role and who are showing the appropriate biomarkers.
NR
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 1.90p |
Change Today | -0.14p |
% Change | -6.86 % |
52 Week High | 3.42 |
52 Week Low | 0.85 |
Volume | 1,925,128 |
Shares Issued | 416.44m |
Market Cap | £7.91m |
RiskGrade | 328 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
16:28 | 419,759 @ 2.00p |
16:29 | 20,000 @ 2.00p |
16:29 | 47,619 @ 2.01p |
16:28 | 69,550 @ 2.00p |
16:28 | 250,000 @ 2.00p |
You are here: research